Gilead Sciences Stock Price, News & Analysis (NASDAQ:GILD)

$75.88 1.66 (2.24 %)
(As of 12/12/2017 01:14 AM ET)
Previous Close$74.22
Today's Range$74.39 - $76.27
52-Week Range$63.76 - $86.27
Volume9.18 million shs
Average Volume9.20 million shs
Market Capitalization$99.41 billion
P/E Ratio7.75
Dividend Yield2.80%
Beta1.13

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:GILD
CUSIP37555810
Phone+1-650-5743000

Debt

Debt-to-Equity Ratio1.10%
Current Ratio3.68%
Quick Ratio3.56%

Price-To-Earnings

Trailing P/E Ratio7.75
Forward P/E Ratio8.90
P/E Growth-1.24

Sales & Book Value

Annual Sales$30.39 billion
Price / Sales3.26
Cash Flow$12.88 per share
Price / Cash5.89
Book Value$14.70 per share
Price / Book5.16

Profitability

Trailing EPS$8.79
Net Income$13.50 billion
Net Margins42.22%
Return on Equity57.15%
Return on Assets21.14%

Miscellaneous

Employees9,000
Outstanding Shares1,306,270,000

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Thursday, October 26th. Investors of record on Friday, December 15th will be given a dividend of $0.52 per share on Thursday, December 28th. This represents a $2.08 annualized dividend and a dividend yield of 2.74%. The ex-dividend date is Thursday, December 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings data on Thursday, October, 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.14. The biopharmaceutical company had revenue of $6.51 billion for the quarter, compared to analysts' expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company's quarterly revenue was down 13.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.75 EPS. View Gilead Sciences' Earnings History.

When will Gilead Sciences make its next earnings announcement?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Gilead Sciences.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

27 equities research analysts have issued 12-month price targets for Gilead Sciences' stock. Their forecasts range from $68.00 to $96.00. On average, they expect Gilead Sciences' stock price to reach $85.42 in the next year. View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • 1. Maxim Group analysts commented, "We returned from Beijing, China and listened as Tim Moore, EVP of Technical Operations and the CEO of Fosun Kite Biotechnology co. (Richard Wang) presented manufacturing plans for the launch of Yescarta, and the opportunity in China (see the slides in the pages that follow). Suffice to say, we were impressed and left clear with the notion that Gilead (and Kite) can overcome manufacturing challenges to commercialize in the U.S. and globally, especially China, this new innovative therapy. As a result, we are upgrading Gilead to Buy, from Hold and establishing a $94 price target." (11/30/2017)
  • 2. According to Zacks Investment Research, "Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. However, the HCV franchise continued to witness slowdown as a result of competitive and pricing pressure. Higher discounts and payer mix continue to hurt sales. The company expects that the persistent decline in HCV patient starts will impact sales along with increased competition which will impact both patient share and pricing. While the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens, Gilead will lose exclusivity for Viread in 2017 in some countries which should impact sales. TOn a positive note, Gilead recently acquired Kite Pharma to foray into the CAR T therapy space which represents immense potential at this juncture . Shares of the company have outperformed the industry so far in 2017." (10/18/2017)
  • 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
  • 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 19,599,824 shares, a drop of 18.9% from the October 13th total of 24,156,580 shares. Based on an average trading volume of 10,442,870 shares, the short-interest ratio is currently 1.9 days. Approximately 1.5% of the shares of the company are sold short.

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

  • John C. Martin Ph.D., Executive Chairman of the Board (Age 65)
  • John F. Milligan Ph.D., Chief Executive Officer, Director (Age 55)
  • Robin L. Washington, Chief Financial Officer, Executive Vice President (Age 54)
  • Kevin B. Young, Chief Operating Officer (Age 59)
  • Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer (Age 61)
  • Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs (Age 51)
  • James R. Meyers, Executive Vice President - Worldwide Commercial Operations (Age 52)
  • John F. Cogan Jr. Ph.D., Lead Independent Director (Age 69)
  • Kelly A. Kramer, Independent Director (Age 49)
  • Kevin E. Lofton, Independent Director (Age 62)

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (2.30%), Parnassus Investments CA (1.43%), Capital International Investors (0.86%), Boston Partners (0.80%), Legal & General Group Plc (0.54%) and American International Group Inc. (0.49%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan, Bank of New York Mellon Corp, Parnassus Investments CA, American Century Companies Inc., Principal Financial Group Inc., Woodford Investment Management Ltd, Bessemer Group Inc. and Schroder Investment Management Group. Company insiders that have sold Gilead Sciences company stock in the last year include Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Sanders Capital LLC, Skandinaviska Enskilda Banken AB publ, Ameriprise Financial Inc., Amundi Pioneer Asset Management Inc., Assenagon Asset Management S.A., Pictet Asset Management Ltd. and Mondrian Investment Partners LTD. View Insider Buying and Selling for Gilead Sciences.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of Gilead Sciences stock can currently be purchased for approximately $75.88.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $99.41 billion and generates $30.39 billion in revenue each year. The biopharmaceutical company earns $13.50 billion in net income (profit) each year or $8.79 on an earnings per share basis. Gilead Sciences employs 9,000 workers across the globe.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DR, FOSTER CITY, CA 94404, United States. The biopharmaceutical company can be reached via phone at +1-650-5743000 or via email at [email protected]


MarketBeat Community Rating for Gilead Sciences (GILD)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  1,629 (Vote Outperform)
Underperform Votes:  589 (Vote Underperform)
Total Votes:  2,218
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Gilead Sciences (NASDAQ:GILD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.692.692.712.64
Ratings Breakdown: 0 Sell Rating(s)
10 Hold Rating(s)
18 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
18 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
18 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $85.73$86.68$84.90$84.68
Price Target Upside: 15.51% upside18.40% upside2.83% upside28.19% upside

Gilead Sciences (NASDAQ:GILD) Consensus Price Target History

Price Target History for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2017Maxim GroupSet Price TargetBuy$94.00MediumView Rating Details
12/7/2017Credit Suisse GroupReiterated RatingBuy$82.00MediumView Rating Details
11/13/2017ArgusDowngradeBuy -> Hold$73.25 -> $73.77N/AView Rating Details
11/8/2017MizuhoBoost Price TargetBuy$77.00 -> $83.00N/AView Rating Details
10/27/2017BMO Capital MarketsLower Price TargetOutperform$89.00 -> $83.00N/AView Rating Details
10/25/2017J P Morgan Chase & CoSet Price TargetBuy$85.00N/AView Rating Details
10/19/2017Leerink SwannBoost Price TargetMarket Perform$84.00 -> $85.00N/AView Rating Details
10/19/2017William BlairReiterated RatingBuyN/AView Rating Details
10/19/2017Berenberg BankSet Price TargetBuy$96.00N/AView Rating Details
10/11/2017BarclaysReiterated RatingOverweight -> Overweight$90.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$77.00 -> $83.00N/AView Rating Details
10/5/2017CIBCInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
10/5/2017OppenheimerInitiated CoverageMarket PerformN/AView Rating Details
10/5/2017Jefferies GroupInitiated CoverageHold -> PositiveN/AView Rating Details
10/4/2017Bank of AmericaLower Price TargetNeutral$87.00 -> $86.00LowView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$94.00LowView Rating Details
9/6/2017Wells Fargo & CompanyBoost Price TargetMarket Perform$73.00 -> $81.00LowView Rating Details
8/31/2017CowenReiterated RatingOutperform$90.00MediumView Rating Details
8/31/2017Deutsche BankReiterated RatingBuy$81.00MediumView Rating Details
8/28/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
8/29/2017Robert W. BairdReiterated RatingOutperform$87.00LowView Rating Details
7/26/2017Redburn PartnersInitiated CoverageBuyMediumView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
3/13/2017Goldman Sachs GroupReiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
2/8/2017CitigroupDowngradeBuy -> Neutral$87.00 -> $76.00N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Gilead Sciences (NASDAQ:GILD) Earnings History and Estimates Chart

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018$1.71N/AView Earnings Details
10/26/2017Q3 2017$2.13$2.27$6.40 billion$6.51 billionViewN/AView Earnings Details
7/26/2017Q2 2017$2.11$2.56$6.35 billion$7.14 billionViewN/AView Earnings Details
5/2/2017Q1 2017$2.18$2.20$6.66 billion$6.51 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Gilead Sciences (NASDAQ:GILD) Earnings Estimates

2017 EPS Consensus Estimate: $8.10
2018 EPS Consensus Estimate: $6.58
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$2.09$2.42$2.23
Q2 20173$2.01$2.29$2.15
Q3 20174$1.86$2.10$1.96
Q4 20174$1.66$1.85$1.76
Q1 20182$1.58$1.78$1.68
Q2 20182$1.54$1.76$1.65
Q3 20182$1.49$1.74$1.62
Q4 20182$1.52$1.74$1.63
(Data provided by Zacks Investment Research)

Dividends

Gilead Sciences (NASDAQ:GILD) Dividend Information

Next Dividend:12/28/2017
Annual Dividend:$2.08
Dividend Yield:2.74%
Payout Ratio:23.66% (Trailing 12 Months of Earnings)
24.38% (Based on This Year's Estimates)
30.95% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2017quarterly$0.522.7%12/14/201712/15/201712/28/2017
7/26/2017quarterly$0.522.78%9/14/20179/15/20179/28/2017
5/2/2017quarterly$0.523.09%6/14/20176/16/20176/29/2017
2/7/2017quarterly$0.523.11%3/14/20173/16/20173/30/2017
11/1/2016quarterly$0.472.59%12/13/201612/15/201612/29/2016
7/25/2016quarterly$0.472.32%9/14/20169/16/20169/29/2016
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015
(Data available from 1/1/2013 forward)

Insider Trades

Gilead Sciences (NASDAQ GILD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 76.23%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Gregg H AltonEVPSell15,000$74.64$1,119,600.00View SEC Filing  
12/1/2017John C MartinInsiderSell73,333$74.98$5,498,508.34View SEC Filing  
11/13/2017John F MilliganInsiderSell220,000$72.88$16,033,600.00View SEC Filing  
11/1/2017Gregg H AltonEVPSell15,000$74.82$1,122,300.00View SEC Filing  
11/1/2017John C MartinInsiderSell73,333$75.13$5,509,508.29View SEC Filing  
10/2/2017Gregg H AltonEVPSell25,000$82.65$2,066,250.00View SEC Filing  
10/2/2017John C MartinInsiderSell73,333$82.56$6,054,372.48View SEC Filing  
9/7/2017Robin L WashingtonCFOSell51,820$85.00$4,404,700.00View SEC Filing  
9/1/2017Gregg H AltonEVPSell25,000$83.05$2,076,250.00View SEC Filing  
9/1/2017John C MartinInsiderSell73,333$83.11$6,094,705.63View SEC Filing  
8/31/2017James R MeyersEVPSell60,000$83.19$4,991,400.00View SEC Filing  
8/30/2017Gregg H AltonEVPSell50,000$79.00$3,950,000.00View SEC Filing  
8/1/2017Gregg H AltonEVPSell15,000$75.88$1,138,200.00View SEC Filing  
8/1/2017John C MartinInsiderSell73,333$75.86$5,563,041.38View SEC Filing  
7/21/2017Gregg H AltonEVPSell40,000$74.00$2,960,000.00View SEC Filing  
7/3/2017Gregg H AltonEVPSell5,000$71.06$355,300.00View SEC Filing  
7/3/2017John C MartinInsiderSell73,333$71.00$5,206,643.00View SEC Filing  
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.75View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.94View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Gilead Sciences (NASDAQ GILD) News Headlines

Source:
DateHeadline
Gilead Sciences (GILD) PT Set at $94.00 by Maxim GroupGilead Sciences (GILD) PT Set at $94.00 by Maxim Group
www.americanbankingnews.com - December 11 at 5:08 PM
Adverse Sales Growth Make Gilead Sciences (GILD) a Sell - Investorplace.comAdverse Sales Growth Make Gilead Sciences (GILD) a Sell - Investorplace.com
investorplace.com - December 11 at 4:57 PM
Adverse Sales Growth Make Gilead Sciences (GILD) a SellAdverse Sales Growth Make Gilead Sciences (GILD) a Sell
investorplace.com - December 11 at 1:15 PM
Gilead Sciences: Better Data, Better Stock?Gilead Sciences: Better Data, Better Stock?
finance.yahoo.com - December 11 at 10:52 AM
Today’s Research Reports on Stocks to Watch: Gilead Sciences and Alexion PharmaceuticalsToday’s Research Reports on Stocks to Watch: Gilead Sciences and Alexion Pharmaceuticals
finance.yahoo.com - December 11 at 10:52 AM
Is Gilead Sciences, Inc. a Buy?Is Gilead Sciences, Inc. a Buy?
www.fool.com - December 10 at 11:55 AM
Gilead Sciences (GILD) to Acquire Cell Design Labs for $567MGilead Sciences (GILD) to Acquire Cell Design Labs for $567M
www.streetinsider.com - December 8 at 4:42 PM
ETFs with exposure to Gilead Sciences, Inc. : December 8, 2017ETFs with exposure to Gilead Sciences, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 4:42 PM
Gilead Sciences (GILD) and Kite to Acquire Cell Design Labs for up to $567MGilead Sciences (GILD) and Kite to Acquire Cell Design Labs for up to $567M
www.streetinsider.com - December 8 at 10:06 AM
Gilead Sciences To Buy Cell Design Labs In $567 Mln DealGilead Sciences To Buy Cell Design Labs In $567 Mln Deal
www.nasdaq.com - December 8 at 10:06 AM
Gilead Sciences to Acquire Cell Design Labs for $567 MillionGilead Sciences to Acquire Cell Design Labs for $567 Million
www.zacks.com - December 8 at 10:06 AM
Gilead to buy Cell Design Labs for up to $567 mlnGilead to buy Cell Design Labs for up to $567 mln
finance.yahoo.com - December 8 at 10:06 AM
Why Biotech Stocks May Wait A While Before Feeling The LoveWhy Biotech Stocks May Wait A While Before Feeling The Love
finance.yahoo.com - December 8 at 10:06 AM
Notable Two Hundred Day Moving Average Cross - GILDNotable Two Hundred Day Moving Average Cross - GILD
www.nasdaq.com - December 7 at 5:05 PM
Gilead Sciences and Kite to Acquire Cell Design LabsGilead Sciences and Kite to Acquire Cell Design Labs
finance.yahoo.com - December 7 at 5:05 PM
Gilead Sciences to Acquire Cell Design LabsGilead Sciences to Acquire Cell Design Labs
finance.yahoo.com - December 7 at 5:05 PM
Credit Suisse Group Reaffirms Buy Rating for Gilead Sciences (GILD)Credit Suisse Group Reaffirms Buy Rating for Gilead Sciences (GILD)
www.americanbankingnews.com - December 7 at 4:26 PM
Gilead Sciences, Inc. (GILD) Receives Consensus Rating of "Buy" from AnalystsGilead Sciences, Inc. (GILD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 7 at 11:54 AM
Glaxo Who? Why Gileads HIV Drug Could Be the Greatest of All TimeGlaxo Who? Why Gilead's HIV Drug Could Be the 'Greatest of All Time'
finance.yahoo.com - December 6 at 4:49 PM
Why Gilead Could Have 'Greatest' Ever In HIV Drug LaunchesWhy Gilead Could Have 'Greatest' Ever In HIV Drug Launches
finance.yahoo.com - December 6 at 4:49 PM
John C. Martin Sells 73,333 Shares of Gilead Sciences, Inc. (GILD) StockJohn C. Martin Sells 73,333 Shares of Gilead Sciences, Inc. (GILD) Stock
www.americanbankingnews.com - December 5 at 8:34 PM
Gilead Sciences, Inc. (GILD) EVP Sells $1,119,600.00 in StockGilead Sciences, Inc. (GILD) EVP Sells $1,119,600.00 in Stock
www.americanbankingnews.com - December 5 at 8:34 PM
Gilead Sciences, Emory and others launch $100 million initiative to address HIV/AIDS crisis in SouthGilead Sciences, Emory and others launch $100 million initiative to address HIV/AIDS crisis in South
www.bizjournals.com - December 5 at 4:44 PM
Quant Score Metrics Restrict Gilead Sciences (GILD) Ratings Upgrade to Hold - Investorplace.comQuant Score Metrics Restrict Gilead Sciences (GILD) Ratings Upgrade to Hold - Investorplace.com
investorplace.com - December 5 at 11:50 AM
With HIV infection rates soaring in South, Gilead pledges $100 million - San Francisco Business TimesWith HIV infection rates soaring in South, Gilead pledges $100 million - San Francisco Business Times
www.bizjournals.com - December 5 at 11:50 AM
Gilead & 3 Other Drug Stocks in Focus this World AIDS DayGilead & 3 Other Drug Stocks in Focus this World AIDS Day
www.nasdaq.com - December 1 at 5:26 PM
Why Gileads Highly Touted Stock Has No UpsideWhy Gilead's Highly Touted Stock Has No Upside
finance.yahoo.com - December 1 at 5:26 PM
Maxim Explains Why Gilead Sciences Is A Now A BuyMaxim Explains Why Gilead Sciences Is A Now A Buy
www.benzinga.com - November 30 at 4:45 PM
This is how Jay Powell might slip up in the Senate today and move the marketsThis is how Jay Powell might slip up in the Senate today and move the markets
finance.yahoo.com - November 30 at 4:45 PM
Gilead’s Cell Therapy Opportunity Tempts Maxim to Join the Bullish CampGilead’s Cell Therapy Opportunity Tempts Maxim to Join the Bullish Camp
finance.yahoo.com - November 30 at 4:45 PM
Gilead Sciences Stock Upgraded: This Is the Power of FreeGilead Sciences Stock Upgraded: This Is the Power of Free
www.fool.com - November 30 at 2:59 PM
Maxim Group Upgrades Gilead Sciences (GILD) to BuyMaxim Group Upgrades Gilead Sciences (GILD) to Buy
www.americanbankingnews.com - November 30 at 12:42 PM
Gilead Sciences, Inc. :GILD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Gilead Sciences, Inc. :GILD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 10:42 AM
Gilead Stock Could Have 50% UpsideGilead Stock Could Have 50% Upside
finance.yahoo.com - November 30 at 10:42 AM
Stocks are taking a turkey nap this weekStocks are taking a turkey nap this week
finance.yahoo.com - November 29 at 5:03 PM
Smart money is planning for the end of this bull market: NYSE traderSmart money is planning for the end of this bull market: NYSE trader
finance.yahoo.com - November 29 at 5:03 PM
This market feels like Groundhog Day: NYSE traderThis market feels like Groundhog Day: NYSE trader
finance.yahoo.com - November 29 at 5:03 PM
Amazon, Gilead, Nordstrom: Fast Money Picks For November 28Amazon, Gilead, Nordstrom: Fast Money Picks For November 28
www.benzinga.com - November 29 at 10:13 AM
New Pharma ETF PILL : What Investors Need to KnowNew Pharma ETF PILL : What Investors Need to Know
finance.yahoo.com - November 28 at 4:43 PM
Gilead (GILD) Down 7.9% Since Earnings Report: Can It Rebound?Gilead (GILD) Down 7.9% Since Earnings Report: Can It Rebound?
finance.yahoo.com - November 28 at 9:13 AM
"Fast Money" final trades: GILD, AMZN and more"Fast Money" final trades: GILD, AMZN and more
finance.yahoo.com - November 28 at 9:13 AM
ETFs with exposure to Gilead Sciences, Inc. : November 27, 2017ETFs with exposure to Gilead Sciences, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 5:40 PM
Gilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.70 BillionGilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.70 Billion
www.americanbankingnews.com - November 27 at 6:50 AM
J&J & Glaxo's Jucala Approval Puts Spotlight on HIV SpaceJ&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space
finance.yahoo.com - November 24 at 4:42 PM
Gilead: Attractive After Big Retreat? - Seeking AlphaGilead: Attractive After Big Retreat? - Seeking Alpha
seekingalpha.com - November 24 at 10:23 AM
Can Gilead Sciences Inc’s (GILD) ROE Continue To Surpass The Industry Average?Can Gilead Sciences Inc’s (GILD) ROE Continue To Surpass The Industry Average?
finance.yahoo.com - November 23 at 4:36 PM
J&J & Glaxo Get FDA Approval for First Two-Drug HIV RegimenJ&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
finance.yahoo.com - November 22 at 7:53 PM
Gilead: The Leader of the Pack…or Just Another Follower?Gilead: The Leader of the Pack…or Just Another Follower?
finance.yahoo.com - November 22 at 7:53 PM
How Merck’s Zepatier and Isentress Are PositionedHow Merck’s Zepatier and Isentress Are Positioned
finance.yahoo.com - November 21 at 7:03 PM
The 1 Thing Missing From Gilead Sciences' 2018 Priority ListThe 1 Thing Missing From Gilead Sciences' 2018 Priority List
finance.yahoo.com - November 21 at 7:03 PM

SEC Filings

Gilead Sciences (NASDAQ:GILD) SEC Filings

DateFilerForm TypeView
12/05/2017
6:49 PM
Gilead Sciences (Issuer)
MARTIN JOHN C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/05/2017
5:17 PM
Alton Gregg H (Reporting)
Gilead Sciences (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Gilead Sciences (NASDAQ:GILD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Gilead Sciences (NASDAQ GILD) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.